Literature DB >> 6112035

Antagonism of vasodepressor and gastric secretory responses to histamine by the H2-receptor antagonists, ranitidine and cimetidine, in the anaesthetized dog.

M J Daly, J M Humphray, R Stables.   

Abstract

1 The new H2-receptor antagonist, ranitidine, has been compared with cimetidine as an inhibitor of gastric acid secretion in the anaesthetized dog. 2 Both ranitidine and cimetidine given intravenously inhibited histamine-induced gastric secretion in a dose-related manner. Ranitidine was 4.2 times more potent than cimetidine when given as an intravenous infusion and 9.6 times more potent as an intravenous bolus dose. 3 In a separate series of experiments, ranitidine was compared with cimetidine as an antagonist of vasodepressor responses to histamine. Mepyramine alone displaced the histamine dose-response curve to the right. After a maximally effective dose of mepyramine, further displacement could be achieved with ranitidine and cimetidine, ranitidine being 19.2 times more potent than cimetidine. 4 Ranitidine alone has no effect on vasodepressor response curves to histamine, acetylcholine or (-)-isoprenaline or on vasopressor response curves to phenylephrine. 5 These results indicate that displacement of the histamine dose-response curve after mepyramine blockade by ranitidine and cimetidine is due to selective H2-receptor antagonism.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6112035      PMCID: PMC2071555          DOI: 10.1111/j.1476-5381.1981.tb09104.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

1.  An analysis of the depressor responses to histamine in the cat and dog: involvement of both H1- and H2-receptors.

Authors:  J W Black; D A Owen; M E Parsons
Journal:  Br J Pharmacol       Date:  1975-07       Impact factor: 8.739

2.  Factors affecting histamine-stimulated gastric secretion in anaesthetized dogs.

Authors:  J W BLACK; E W FISHER; A N SMITH
Journal:  J Physiol       Date:  1958-04-03       Impact factor: 5.182

3.  The physiological action of beta-iminazolylethylamine.

Authors:  H H Dale; P P Laidlaw
Journal:  J Physiol       Date:  1910-12-31       Impact factor: 5.182

4.  Further observations on the action of beta-iminazolylethylamine.

Authors:  H H Dale; P P Laidlaw
Journal:  J Physiol       Date:  1911-10-20       Impact factor: 5.182

5.  Antagonism of vasodepressor and gastric secretory responses to histamine by ranitidine and cimetidine in the anaesthetised dog [proceedings].

Authors:  M J Daly; J M Humphray; R Stables
Journal:  Br J Pharmacol       Date:  1979-11       Impact factor: 8.739

6.  Identification and specific blockade of two receptors for histamine in the cardiovascular system.

Authors:  J R Powell; M J Brody
Journal:  J Pharmacol Exp Ther       Date:  1976-01       Impact factor: 4.030

7.  The measurement of dog gastric mucosal blood flow by radioactive aniline clearance compared with amidopyrine clearance.

Authors:  B P Curwain; P Holton
Journal:  J Physiol       Date:  1973-02       Impact factor: 5.182

8.  Inhibition of gastric acid secretion in the dog by the H2-receptor antagonists, ranitidine, cimetidine, and metiamide.

Authors:  M J Daly; J M Humphray; R Stables
Journal:  Gut       Date:  1980-05       Impact factor: 23.059

9.  Relaxant action of histamine on rabbit trachea: possible existence of third histamine receptor subtype.

Authors:  N Chand; P Eyre; L DeRoth
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-02
  9 in total
  2 in total

Review 1.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

Review 2.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.